Human Flt-1 is a type I transmembrane receptor for the angiogenic cytokine, VEGF. Alternate splicings of human VEGF R1 mRNA encode soluble, secreted isoforms that can function as inhibitors of VEGF. One, designated sFLT1-14 or sFLT1-e15a, encodes a 733aa, 95-135kD form that is produced by non-endothelial cells, notably by degenerative syncytiotrophoblasts within syncytial knots in the placenta. This form appears to be unique to primates and is produced in excess during preeclampsia of pregnancy. The peptide used as an immunogen is not present within either the full-length or alternate secreted forms of the protein.
Applications:
Suitable for use in Western Blot and Direct ELISA. Other applications not tested.
Recommended Dilutions:
Western Blot: 2ug/ml using human serum (preeclampsia)
Optimal dilutions to be determined by the researcher.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.